# Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP

> **NCT01868035** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 15 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** tositumomab and iodine I-131 tositumomab

## Key facts

- **NCT ID:** NCT01868035
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-05
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01868035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01868035, "Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01868035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*